Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions, operating in Israel, China, Switzerland, Canada, the United States, and internationally. Its products include Twyneo, a once-daily, non-antibiotic topical cream for acne vulgaris, and Epsolay, a once-daily topical cream for papulopustular (subtype II) rosacea. The company is also developing SGT-610, in Phase 3 clinical trials for Gorlin Syndrome, and SGT-210, which has completed Phase I clinical trials for Olmsted syndrome. It collaborates with Padagis Israel Pharmaceuticals Ltd. and holds license agreements with Galderma Holding SA and Searchlight Pharma Inc. Incorporated in 1997, Sol-Gel Technologies Ltd. is headquartered in Ness Ziona, Israel.